№ files_lp_3_process_7_061677
File format: docx
Character count: 5805
File size: 72 KB
Official NHS committee decision record outlining formulary statuses, commissioning positions, and NICE technology appraisal outcomes for specific medicines in Humber and North Yorkshire in November 2025.
Year:
2025
Month:
November
Region:
Humber and North Yorkshire
Country:
United Kingdom
Document type:
Committee decision summary
Organisation:
Humber and North Yorkshire Area Prescribing Committee (HNY APC)
Approved by:
HNY APC
Date of approval:
3 December 2025
Reviewed by:
CPC
Scheduled review:
January meeting
Legal framework:
NICE technology appraisals implementation within NHS
Scope:
Medicines commissioning, formulary status, shared care protocols
Intended audience:
NHS healthcare professionals
Contact organisation:
HNY APC Professional Secretariat, Regional Drug and Therapeutics Centre, Newcastle upon Tyne
Usage restriction:
Not for commercial or marketing purposes
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2025
Region / City:
Humber and North Yorkshire
Subject:
Pharmaceutical guidelines, drug and treatment protocols
Document Type:
Decision summary
Organization:
HNY APC (Humber and North Yorkshire Area Prescribing Committee)
Author:
HNY APC
Target Audience:
NHS Healthcare Professionals
Approval Date:
2nd July 2025
Date of Changes:
June 2025
Year:
2025
Region / City:
Humber and North Yorkshire
Theme:
Medicines Optimisation, Pharmaceutical Services
Document Type:
Meeting Minutes
Organisation:
Humber and North Yorkshire Integrated Care Board (NHS HNY ICB)
Author:
Laura Angus (Chair)
Target Audience:
Healthcare professionals, pharmacists, healthcare managers
Period of Validity:
N/A
Approval Date:
N/A
Date of Changes:
N/A
Year:
2025
Region / City:
Humber and North Yorkshire
Topic:
Clinical and Pharmaceutical Policy
Document Type:
Meeting Minutes
Organ / Institution:
Humber and North Yorkshire ICB
Author:
Nigel Wells
Target Audience:
Health professionals, pharmacists, healthcare administrators
Period of Action:
January 2025
Approval Date:
8th January 2025
Date of Modifications:
N/A
Year:
2024/25
Region / City:
Not specified
Topic:
Continuing Professional Development (CPD) for Dyslexia Guild Members
Document Type:
Membership Requirement Guidelines
Organization:
The Dyslexia Guild
Author:
Not specified
Target Audience:
Members of The Dyslexia Guild, APC holders
Period of validity:
Annual CPD requirement
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2021
Study:
Global Burden of Disease Study 2021 (GBD 2021)
Topic:
Epidemiological modeling and data sources for COPD incidence and mortality
Document type:
Technical nomenclature and methodological description
Field:
Epidemiology and public health
Model:
Age–Period–Cohort (APC) model
Data source system:
Global Health Data Exchange (GHDx)
Database:
Causes of Death (CoD) database
Modeling tools:
DisMod-MR; MR-BRT (Bayesian regularized model with temporal smoothing)
Geographic coverage:
204 countries and territories
Health condition:
Chronic Obstructive Pulmonary Disease (COPD)
Data source types:
surveys, censuses, vital registration, surveillance systems, cancer registries, police records, sibling history, survey/census data, minimally invasive tissue sample diagnoses
Reference parameters:
reference age group (a0), reference period (p0), reference cohort (c0)
Statistical measures:
Net Drift, Age Deviations, Period Deviations, Cohort Deviations, Longitudinal Age Curve, Period Rate Ratios, Cohort Rate Ratios, Local Drifts
Data access platform:
Global Health Data Exchange citation tool
File format available:
CSV metadata export
Outlier criteria:
exclusion of implausible values, conflicts with age or temporal patterns, and inconsistencies with comparable data sources
Year:
2013
Region / City:
Waterloo
Topic:
Mechanical testing of sheet materials
Document Type:
Meeting Agenda
Organization:
Novelis, CANMET, Amino
Author:
Unknown
Target Audience:
Project partners
Effective Period:
October 4, 2013
Approval Date:
October 4, 2013
Date of Changes:
Not mentioned
Note:
Summary of the document
Version:
HNY v3.0
Replaces version:
HNY v2.0
Clinical content last reviewed:
November 2023
Next review date:
July 2028
Local approval:
1st October 2025
Target population:
Adults aged 18 and over, excluding cancer care
Indications:
Licensed and off-label use in rheumatoid arthritis, Crohn’s disease, psoriasis, psoriatic arthritis, and other chronic inflammatory conditions
Administration routes:
Oral, subcutaneous
Monitoring requirements:
Blood tests, infection screening, vaccination advice, renal function assessment, pregnancy considerations
Responsible organizations:
HNY ICB, RDTC
Document type:
Shared Care Protocol
Contextual description:
Clinical guidance source detailing licensed and off-label methotrexate indications, administration, monitoring, and transfer protocols between specialist and primary care for adults in non-cancer services.
Year:
2025
Region / City:
Humber and North Yorkshire
Subject:
Pharmaceutical guidelines, drug and treatment protocols
Document Type:
Decision summary
Organization:
HNY APC (Humber and North Yorkshire Area Prescribing Committee)
Author:
HNY APC
Target Audience:
NHS Healthcare Professionals
Approval Date:
2nd July 2025
Date of Changes:
June 2025
Year:
2023
Region / City:
Humber and North Yorkshire
Topic:
Learning and Development Policy
Document Type:
Policy
Organization:
Humber and North Yorkshire Integrated Care Board (ICB)
Author:
Senior Manager: Organisational Development & Learning and Development Lead
Target Audience:
ICB Employees
Approval Date:
07/09/2023
Amendment History:
7/9/23 - Updated policy from prior CCG organisations to ICB
Policy Number:
50
Version Number:
0.22
Equality Impact Assessment:
22/08/2023
Scope:
All Humber and North Yorkshire ICB employees
Mandatory Training:
Yes
Study Leave:
Yes
Year:
2025
Region / City:
Humber and North Yorkshire
Topic:
Establishment of Joint Committees
Document Type:
Report
Organization / Institution:
Humber and North Yorkshire Integrated Care Board
Author:
Natalie Caphane
Target Audience:
ICB Board members, Local Authority leaders
Period of Effect:
April 2025 - onwards
Approval Date:
March 12, 2025
Date of Changes:
N/A
Version:
HNY v1.0
Replaces version:
RDTC v1.0
Date published:
April 2025
Clinical content last reviewed:
October 2023
Next review date:
October 2025
Previous version publication date:
7th December 2023
Local approval date:
2nd April 2025
Approved by:
Humber and North Yorkshire ICB
Document type:
Shared Care Protocol
Therapeutic area:
Cardiology
Medicine:
Dronedarone
Target population:
Adults aged 18 years and over
Indication:
Maintenance of sinus rhythm after successful cardioversion in clinically stable adult patients with paroxysmal or persistent atrial fibrillation
Recommended dose:
400 mg twice daily with morning and evening meals
Initiation responsibility:
Specialist only
Prescribing restriction:
Not to be initiated in primary care for new patients
Monitoring requirements:
Liver function tests, urea and electrolytes including potassium and magnesium, serum creatinine, ECG
Regulatory references:
NICE TA 197; NICE NG 196
Intended audience:
NHS healthcare professionals
Geographical scope:
North West, North East and Yorkshire ICBs
Commercial use restriction:
Not permitted for commercial or marketing purposes
Year:
2025
Region / City:
Humber and North Yorkshire
Subject:
Pharmaceutical guidelines, drug and treatment protocols
Document Type:
Decision summary
Organization:
HNY APC (Humber and North Yorkshire Area Prescribing Committee)
Author:
HNY APC
Target Audience:
NHS Healthcare Professionals
Approval Date:
2nd July 2025
Date of Changes:
June 2025
Year:
2023
Region / City:
N/A
Subject:
Genetic differentiation, metabolic analysis
Document Type:
Research Supplement
Institution:
N/A
Author:
N/A
Target Audience:
Researchers in genetics and agriculture
Period of Validity:
N/A
Approval Date:
N/A
Modification Date:
N/A
Document Type:
Supplementary statistical tables
Research Field:
Epidemiology; Public Health; Neurology
Topic:
Associations between smoking status, smoking dosage (pack-years), and risk of dementia
Health Outcomes Studied:
All-cause dementia; Alzheimer’s dementia; vascular dementia
Exposure Variables:
Smoking initiation, smoking cessation, sustained smoking, pack-year exposure
Population Size:
1,073,517 non-smokers and multiple smoking status groups
Statistical Measures:
Incidence rate per 1000 person-years; hazard ratio with 95% confidence interval
Observation Metric:
Person-years of follow-up
Analytical Approach:
Sensitivity analysis and subgroup interaction analysis
Adjusted Covariates:
Sex; age; low income; alcohol consumption; regular physical activity; body mass index; hearing loss; diabetes mellitus; hypertension; dyslipidemia
Subgroup Factors:
Low income; alcohol consumption; physical activity; obesity; hearing loss; diabetes mellitus; hypertension; dyslipidemia
Purpose:
Quantitative assessment of how smoking behavior and demographic or health factors relate to dementia incidence
Source Context:
Supplementary material accompanying an epidemiological research study
Document type:
Supplementary table
Study cohort:
Rotterdam cohort
Topic:
Clinicopathological characteristics and treatment response
Medical field:
Oncology
Variables described:
Age, tumor characteristics, response to first-line tamoxifen
Subgroups:
ISGHIGH, ISGLOW
Statistical analysis:
Statistical tests for subgroup differences indicated for each variable
Treatment referenced:
First-line tamoxifen
Population:
Patients included in the Rotterdam cohort
Section:
Supplementary material
Table number:
2
Year:
2026
Region:
Multicenter study
Topic:
Cystic fibrosis treatment outcomes
Document type:
Clinical study table
Institution:
University medical centers
Population:
Patients with cystic fibrosis
Treatment groups:
Never treated with CFTR modulators; Switched from lumacaftor/ivacaftor to ETI
Parameters measured:
Age, sex, sweat chloride, FEV1, FVC, BMI, pancreatic insufficiency, diabetes, chronic infections, CRP, ESR, leukocyte and neutrophil counts, platelets, IgG, albumin, hemoglobin, HbA1c, glucose
Statistical methods:
Chi-square, t-test, Mann-Whitney test
Data source:
ETI treatment initiation visit
Year:
Not specified
Region / City:
Not specified
Topic:
Respiratory infections, coinfections
Document type:
Research table
Author:
Not specified
Target audience:
Researchers, medical professionals
Period of validity:
Not specified
Approval date:
Not specified
Date of amendments:
Not specified
The document provides a table detailing the types and frequencies of viral and bacterial respiratory coinfections in two subgroups:
invasive GAS and severe GAS infections.